Another MCL-1 specific inhibitor AZD-5991 shows significant anti-tumor activity in vivo with complete regression in mouse models of MM and AML, based on which a phase I clinical trial has been set up for patients with hematological malignancies (NCT03218683) [164]. This evidence concerns the gene MCL1 and Miyoshi myopathy.